Analyzing tumor cells in blood to improve treatment for advanced prostate cancer
Genomic profiling of single circulating tumor cells in the precision medicine of metastatic prostate cancer
['FUNDING_R01'] · THOMAS JEFFERSON UNIVERSITY · NIH-10843884
This study is looking at new ways to analyze cancer cells in the blood of men with hard-to-treat prostate cancer, so doctors can better tailor treatments to each patient's needs as the cancer changes over time.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | THOMAS JEFFERSON UNIVERSITY (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-10843884 on ClinicalTrials.gov |
What this research studies
This research focuses on metastatic castration-resistant prostate cancer (mCRPC), a severe form of prostate cancer that is difficult to treat. The study aims to develop non-invasive methods to analyze circulating tumor cells (CTCs) found in the blood, which can provide real-time insights into the tumor's genomic characteristics. By understanding these characteristics, the research seeks to personalize treatment strategies for patients, adapting to changes in the tumor's profile over time. This approach aims to overcome the limitations of traditional tissue biopsies, which are often challenging to perform in mCRPC cases.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metastatic castration-resistant prostate cancer who may benefit from personalized treatment strategies.
Not a fit: Patients with early-stage prostate cancer or those who do not have metastatic disease may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment options for patients with advanced prostate cancer.
How similar studies have performed: Previous research has shown promise in using liquid biopsies for cancer monitoring, indicating that this approach could be effective for mCRPC as well.
Where this research is happening
PHILADELPHIA, UNITED STATES
- THOMAS JEFFERSON UNIVERSITY — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: YANG, HUSHAN — THOMAS JEFFERSON UNIVERSITY
- Study coordinator: YANG, HUSHAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Center, Cancer Patient, Cancer Prognosis, Cancers